RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ARYx Therapeutics Stock

ARYx Therapeutics EBIT 2024

ARYx Therapeutics EBIT

0 USD

Ticker

ARYX

ISIN

US0433871094

In 2024, ARYx Therapeutics's EBIT was 0 USD, a 0% increase from the 0 USD EBIT recorded in the previous year.

The ARYx Therapeutics EBIT history

YEAREBIT (undefined USD)
2011e-
2010e-
2009-
2008-
2007-
2006-
2005-
2004-
2003-
2002-

ARYx Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ARYx Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ARYx Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ARYx Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ARYx Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ARYx Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ARYx Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ARYx Therapeutics’s growth potential.

ARYx Therapeutics Revenue, EBIT and net profit per share

DateARYx Therapeutics RevenueARYx Therapeutics EBITARYx Therapeutics Net Income
2011e0 undefined0 undefined-88.91 M undefined
2010e0 undefined0 undefined-60.24 M undefined
20090 undefined-31.24 M undefined-33.17 M undefined
200819.72 M undefined-30.42 M undefined-31.22 M undefined
20074.16 M undefined-28.8 M undefined-27.56 M undefined
20064.74 M undefined-28.29 M undefined-27.33 M undefined
20050 undefined-28.17 M undefined-27.96 M undefined
20040 undefined-21.33 M undefined-20.83 M undefined
20030 undefined-14.06 M undefined-13.97 M undefined
20020 undefined-3.72 M undefined-3.64 M undefined

ARYx Therapeutics stock margins

The ARYx Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ARYx Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ARYx Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ARYx Therapeutics's sales revenue. A higher gross margin percentage indicates that the ARYx Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ARYx Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ARYx Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ARYx Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ARYx Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ARYx Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ARYx Therapeutics Margin History

ARYx Therapeutics Gross marginARYx Therapeutics Profit marginARYx Therapeutics EBIT marginARYx Therapeutics Profit margin
2011e98.82 %0 %0 %
2010e98.82 %0 %0 %
200998.82 %0 %0 %
200898.82 %-154.21 %-158.27 %
200793.7 %-692.64 %-662.84 %
200655.35 %-596.92 %-576.66 %
200598.82 %0 %0 %
200498.82 %0 %0 %
200398.82 %0 %0 %
200298.82 %0 %0 %

ARYx Therapeutics Aktienanalyse

What does ARYx Therapeutics do?

ARYx Therapeutics Inc is a pharmaceutical company founded in 1997 and based in Fremont, California. The company focuses on developing innovative patented therapies for the treatment of heart diseases and other metabolic diseases. The company's business model is based on recognizing the need for new and more effective medications and focusing on the discovery and development of such therapies. ARYx Therapeutics relies on a network of experienced professionals and a rigorous research and development program. ARYx Therapeutics has several divisions, including the development of therapies for the treatment of cardiac arrhythmias, as well as metabolic diseases such as diabetes and hypercholesterolemia. In addition, the company has developed a range of products that interact with the body in innovative ways by activating or blocking specific receptors. ARYx Therapeutics' most well-known product is the antiarrhythmic drug Dronedaron. It is the first antiarrhythmic drug to receive the safety standards of the US Food and Drug Administration (FDA) and offers an effective, safe, and well-tolerated treatment for atrial fibrillation. Dronedaron is currently approved in Europe and the US and is used worldwide by doctors and hospitals as an important treatment option. Another successful product from ARYx Therapeutics is the therapeutic agent NTP-2007. It was developed to increase insulin sensitivity and improve blood sugar control in patients with type 2 diabetes. NTP-2007 utilizes a novel mechanism that enhances the effect of insulin in the body without lowering blood sugar levels. It is currently being tested in clinical trials and showing promising results. Another promising product from ARYx Therapeutics is the anesthetic Fexinidazole. It is an innovative anesthetic that works in a unique way in the body and ensures fast and effective anesthesia without causing negative side effects. Fexinidazole is currently being tested in clinical trials and could prove to be an important innovation in anesthesiology. Overall, ARYx Therapeutics has established itself as a leading company in the research and development of innovative therapies for the treatment of heart diseases and metabolic diseases. The company aims to meet the needs of patients and medical professionals and improve global healthcare by pushing the boundaries of science and technology in medicine. ARYx Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing ARYx Therapeutics's EBIT

ARYx Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ARYx Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ARYx Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ARYx Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ARYx Therapeutics stock

How much did ARYx Therapeutics achieve in EBIT for the current year?

In the current year, ARYx Therapeutics has achieved an EBIT of 0 USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company ARYx Therapeutics.

How has the EBIT of ARYx Therapeutics developed in recent years?

The EBIT of ARYx Therapeutics has increased by 0% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company ARYx Therapeutics?

The EBIT of ARYx Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does ARYx Therapeutics pay?

Over the past 12 months, ARYx Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARYx Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ARYx Therapeutics?

The current dividend yield of ARYx Therapeutics is .

When does ARYx Therapeutics pay dividends?

ARYx Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARYx Therapeutics?

ARYx Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ARYx Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARYx Therapeutics located?

ARYx Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARYx Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARYx Therapeutics from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did ARYx Therapeutics pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of ARYx Therapeutics in the year 2023?

In the year 2023, ARYx Therapeutics distributed 0 USD as dividends.

In which currency does ARYx Therapeutics pay out the dividend?

The dividends of ARYx Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ARYx Therapeutics

Our stock analysis for ARYx Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ARYx Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.